title: Science to practice: can theranostic fullerenes be used to treat brain tumors?
abstract: In an orthotopic brain tumor mouse model, it was shown that convection-enhanced intratumoral delivery of a theranostic metallofullerene (f-Gd₃N@C₈₀) labeled with lutetium 177 (¹⁷⁷Lu) and tetraazacyclododecane tetraacetic acid (DOTA) (¹⁷⁷Lu-DOTA-f-Gd₃N@C₈₀) increases median survival from 21 to 52 days, with a prolonged metallofullerene tumor retention that can be visualized with magnetic resonance (MR) imaging.
authors.affiliation: Department of Radiology The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. jwmbulte@mri.jhu.edu
authors.forename: Jeff W M
authors.initials: JW
authors.lastname: Bulte
mesh_terms: D000818:Animals; D001918:Brachytherapy; D001932:Brain Neoplasms / Q000532:radiotherapy*; D037741:Fullerenes; D005909:Glioblastoma / Q000532:radiotherapy*; D008187:Lutetium / Q000627:therapeutic use*; D051379:Mice; D008819:Mice, Nude; D011868:Radioisotopes / Q000627:therapeutic use*
chemical_list: D037741:Fullerenes; D011868:Radioisotopes; D008187:Lutetium